Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis

doi:10.19803/j.1672-8629.20240365

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the course of anti-infection treatment, and exchange experience related to individualized treatment of patients with pulmonary aspergillus infection secondary to sepsis so as to promote clinical rational drug use. Methods Clinical pharmacists participated in the whole process of anti-infection treatment of a patient with pulmonary aspergillus infection secondary to sepsis by assisting clinicians in formulating and adjusting treatment plans, monitoring voriconazole concentrations in blood, and providing individualized medications and pharmaceutical care. Results The condition of the patient was improved eventually, which offered experience for providing better pharmaceutical care in the future. Conclusion Clinical pharmacists' participation in medications against pulmonary aspergillus infection secondary to sepsis can help ensure the effectiveness and safety of drug treatment for patients so that the worth of clinical pharmacists can be proved.

Key words: sepsis, pulmonary aspergillo, voriconazole, tablrt, monitoring of plasma concentrations, pharmaceutical care, clinical pharmacist

CLC Number:

R994.11

ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu. Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240365

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1064

References

[1] XIAO YL, JIANG T.Prevention and treatment of invasive pulmonary aspergillosis[J].Medical Information(医学信息), 2021, 34(6): 43-46.
[2] BARAC A,KOSMIDIS C,ALASTRUEY-IZQUIERDO A,et al.Chronic pulmonary aspergillosis update: a year in review[J].Med Mycol, 2019, 57(Suppl 2): 104-109.
[3] WANG BB,XU XQ,TAN R,et al.Monitoring and analysis of voriconazole concentration in 73 patients with pulmonary aspergillus[J].Chinese Journal of New Medicine and Clinical Medicine(中国新药与临床杂志), 2022, 41(4): 228-233.
[4] BUPHA-INTR O,BUTTERS C,REYNOLDS G.Australasian antifungal guidelines steering committee. consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than aspergillus in the haematology/oncology setting, 2021[J]. Intern Med J, 2021, 51(Suppl 7): 177-219.
[5] CHEN F,HU SL,LIU JM,et al.A real-world study of voriconazole associated liver injury[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(19): 2006-2010.
[6] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guidelines for diagnosis and management of drug - induced liver injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[7] Emergency Physicians Branch of Chinese Medical Doctor Association, Shock and Sepsis Professional Committee of Chinese Society of Research Hospitals. Guidelines for emergency treatment of sepsis/septic shock in China (2018)[J].Infection, Inflammation, Repair,2019, 20(1): 3-22.
[8] PAUL M,CARRARA E,RETAMAR P.European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)[J]. Clin Microbiol Infect, 2022, 28(4): 521-547.
[9] GILBERT DN,CHAMBERS HF,ELIOPOULOS GM,et al.Sanford’s Antimicrobial Guide[M]. 48th edition. Beijing:China Union Medical College Press, 2018: 224-225.
[10] CHEN T, YANG Y, SHANG XY, et al.Analysis of risk factors and drug resistance of enterococcus faecium infection in intensive care unit[J]. Journal of PLA Medical College(解放军医学院学报), 2023, 44(6): 650-654.
[11] Clinical Microbiology Branch, China Association for the Promotion of International Exchanges in Healthcare, Clinical Microbiology Group, Laboratory Medicine Branch, Chinese Medical Association, Microbiology and Immunology Branch, Chinese Medical Association. Guidelines for mycological examination of invasive mycosis[J]. Chinese Journal of Laboratory Medicine(中华检验医学杂志), 2023, 46(6): 541-557.
[12] LIU X,LI YH,SONG CC.The value of bronchoalveolar lavage fluid G test, GM test and serum galactomannan test in early diagnosis of invasive pulmonary aspergillus infection[J]. Journal of Experimental and Laboratory Medicine(实验与检验医学), 2023, 41(3): 277-279.
[13] Branch of Hematology, Chinese Medical Doctor Association, Chinese Working Group on Invasive Fungal Infections. Diagnostic criteria and therapeutic principles of invasive mycosis in patients with hematological diseases/malignancies(中华内科杂志), 2020, 59(10): 754-763.
[14] Expert Consensus Group on the use of procalcitonin in the graded management of lower respiratory tract infectious diseases in adults. Expert consensus on the application of procalcitonin in the graded management of adult lower respiratory tract infectious diseases[J]. Chinese Journal of Emergency Medicine(中华急诊医学杂志), 2021, 30(4): 393-401.
[15] Working Group on revision of Guidelines for Clinical Use of Antimicrobial Agents. Guiding Principles for Clinical Application of Antibiotics[M]. 2015 edition. Beijing: People’s Medical Publishing House, 2015: 13-14.
[16] SHI WX, YIE XF, CAI YY, et al.Analysis of voriconazole administration interval and dose in antifungal therapy of pulmonary aspergillus disease patients[J].Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2020, 29(3): 223-226.
[17] WANG XB,LIU TT,CHEN DH.Monitoring and analysis of individual voriconazole use in adults[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2023, 48(6): 721-725.
[18] HANG XY, WANG M, SONG XL.Analysis of 60 cases of voriconazole concentration monitoring in hematology department[J].Drug Evaluation(药品评价), 2022, 19(10): 595-598.
[19] WU AL.Effect of hypoproteinemia on antifungal efficacy and valley concentration of voriconazole[D]. Anhui : Anhui Medical University(安徽医科大学), 2022.
[20] AKESUE Y, HANAI Y, ODA K.Japanese antimicrobial therapeutic drug monitoring guideline committee, clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients:consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. Clin Ther, 2022, 44(12): 1604-1623.